In the VCU Massey Cancer Center Project ERIS database involving 600 patients with AML, 28.9% harbored a spliceosome mutation or a mutation in BCOR, EZH2, or STAG2; 36.8% harbored mutations in any of the seven previously mentioned genes or ASXL1 or RUNX1 (Figure 1). This evidence concerns the gene ASXL1 and acute myeloid leukemia.